BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/12/2024 7:29:58 AM | Browse: 140 | Download: 546
 |
Received |
|
2024-07-11 21:32 |
|
Peer-Review Started |
|
2024-07-11 21:32 |
|
First Decision by Editorial Office Director |
|
2024-11-15 07:15 |
|
Return for Revision |
|
2024-11-15 07:15 |
|
Revised |
|
2024-11-18 07:51 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-12-02 02:45 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-12-02 07:26 |
|
Articles in Press |
|
2024-12-02 07:26 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-12-09 00:24 |
|
Publish the Manuscript Online |
|
2024-12-12 07:29 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studies
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mina Tharwat, Ahmed Tawheed and Mohamed El-Kassas |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mohamed El-Kassas, MD, Professor, Department of Endemic Medicine, Faculty of Medicine, Helwan University, Ain Helwan, Cairo 11795, Egypt. m_elkassas@hq.helwan.edu.eg |
| Key Words |
Hepatocellular carcinoma; Atezolizumab; Bevacizumab; Hemorrhage; Side effects |
| Core Tip |
In this article, we comment on the case report by Park et al, published in the recently reporting a fatal intra-tumoral hemorrhage in a patient with hepatocellular carcinoma following successful treatment with atezolizumab/bevacizumab. Multiple predictive factors have been reported to be associated with such condition. They can be categorized as either patient-related (age, systemic hypertension, and use of anticoagulants), liver disease-related (degree of liver decompensation and thrombocytopenia), or tumor-related (portal vein thrombosis). However, future studies are required to assess the long-term safety of this combination in patients with hepatocellular carcinoma. |
| Publish Date |
2024-12-12 07:29 |
| Citation |
Tharwat M, Tawheed A, El-Kassas M. Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studies. World J Clin Cases 2025; 13(9): 99043 |
| URL |
https://www.wjgnet.com/2307-8960/full/v13/i9/99043.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v13.i9.99043 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
